Abstract
G207 is a conditionally replicating derivative of herpes simplex virus (HSV) type-1 strain F engineered with deletions of both γ134.5 loci and a lacZ insertion disabling the UL39 gene. We have demonstrated the efficacy of G207 in treating malignant glial tumors in athymic mice, as well as the safety of intracerebral G207 inoculation in mice and in Aotus nancymai. We sought to determine the safety of G207 inoculation into cerebral malignant glial tumors in humans. Criteria for inclusion into this dose-escalation study were the diagnosis of histologically proven malignant glioma, Karnofsky score ⩾70, recurrence despite surgery and radiation therapy, and an enhancing lesion greater than 1 cm in diameter. Serial magnetic resonance images were obtained for volumetric analysis. The trial commenced at a dose of 106 plaque forming units (p.f.u.) inoculated at a single enhancing site and was completed when the 21st patient was inoculated with 3 × 109 p.f.u. at five sites. While adverse events were noted in some patients, no toxicity or serious adverse events could unequivocally be ascribed to G207. No patient developed HSV encephalitis. We found radiographic and neuropathologic evidence suggestive of anti-tumor activity and long-term presence of viral DNA in some cases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Walker MD et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery New Engl J Med 1980 303: 1323–1329
Subach BR et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series Neurosurgery 1999 45: 17–22; discussion 22–23
Prados MD et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989 Int J Radiat Oncol Biol Phys 1992 23: 3–8
Chamberlain MC, Kormanik P . Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas J Neurooncol 1999 43: 71–78
Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856
Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nature Med 1995 1: 938–943
Hunter WD et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates J Virol 1999 73: 6319–6326
Sundaresan P et al. Attenuated, replication competent herpes simplex virus type I mutant G207: safety evaluation in mice J Virol 2000 74: 3832–3841
Yazaki T et al. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1 Cancer Res 1995 55: 4752–4756
Toda M et al. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity J Immunol 1998 160: 4457–4464
Todo T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus Hum Gene Ther 1999 10: 2741–2755
Peck DJ et al. Cerebral tumor volume calculations using planimetric and eigenimage analysis (see comments) Med Phys 1996 23: 2035–2042
Rampling R et al. Therapeutic replication-competent herpes virus (letter; comment) Nature Med 1998 4: 133
Choucair AK et al. Development of multiple lesions duringradiation therapy and chemotherapy in patients with gliomas J Neurosurg 1986 65: 654–658
Pasquier B et al. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature Cancer 1980 45: 112–125
Hashido M et al. Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan Microbiol Immunol 1999 43: 177–180
Cobbs C, Markert J . Gene therapy of glioma: a review Perspectives Neurol Surg 1999 10: 1–20
Whitley RJ . Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM (eds) Field Virology Lippincott-Raven Publishers: New York 1996 pp 2297–2342
Markert JM et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir Neurosurgery 1993 32: 597–603
Mineta T et al. CNS tumor therapy by attenuated herpes simplex viruses Gene Therapy 1994 1: (Suppl.1) S78
Toda M et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity Hum Gene Ther 1999 10: 385–393
Andreansky S et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins Gene Therapy 1998 5: 121–130
Common Toxicity Criteria. National Institutes of Health, National Cancer Institute: Bethesda 1984
Acknowledgements
We dedicate this paper to the memory of James MacDowell ‘Mac’ Markert, III. We wish to thank Thomas Mikkelson, MD for performing the volumetric MRI measurements; John Gnann, MD for serving as study monitor; Jeff Ostrove, PhD and Paul Johnson, PhD for coordinating virus preparation and performing X-gal staining and Southern blot hybridization. Ann Lowe, MD and Sheryl Osborne, RN, Jolene Lewis, RN and Joy Dritschillo, RN for assistance with protocol preparation; and Fred Lakeman, PhD for PCR.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Markert, J., Medlock, M., Rabkin, S. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7, 867–874 (2000). https://doi.org/10.1038/sj.gt.3301205
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301205
Keywords
This article is cited by
-
Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review
Discover Oncology (2023)
-
Emerging therapies for glioblastoma: current state and future directions
Journal of Experimental & Clinical Cancer Research (2022)
-
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them
British Journal of Cancer (2022)
-
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Nature Medicine (2022)
-
A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
Nature Communications (2022)